Dilraj Grewal, MD, FASRS is the lead PI and Duke is a lead site in the CLARITY phase 3 study, evaluating brepocitinib in non-anterior non-infectious uveitis (NIU). Brepocitinib has been granted Fast Track Designation for NIU by the FDA.
Grewal is quoted in a Modern Retina article, announcing the enrollment of the first patients in the CLARITY study and discussing the results of prior Phase 2 study evaluating brepocitinib in non-anterior NIU,
"FA is the gold standard measurement of posterior segment inflammation in uveitis. The patient-level wide field FA results from the NEPTUNE trial show a clinically meaningful dose-dependent improvement on posterior segment inflammation from treatment with brepocitinib. With these results, the very strong clinical outcomes previously shared are now further supported by dose-dependent improvement on an important biomarker."